Luan Caimar Fuchs
Research Subjects
Luan Caimar Fuchs has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Latest Publications
- Open Access
- 24 February 2026
- Published by Seven Events
- p. 416-427
IMPACT OF SEMAGLUTIDE USE ON LEAN MASS AND SARCOPENIA RISK: AN INTEGRATIVE REVIEW OF CLINICAL EVIDENCE
Semaglutide has emerged as an effective pharmacological strategy for the management of obesity and type 2 diabetes mellitus, promoting significant weight loss. However, its effects on lean mass, muscle function, and the risk of sarcopenia remain under debate, particularly in vulnerable populations such as older adults. The aim of this study was to critically analyze the available clinical evidence regarding the impact of semaglutide on lean mass and sarcopenia risk. This narrative review was conducted based on systematic searches in the PubMed/MEDLINE, SciELO, and ScienceDirect databases, including studies published between 2015 and 2025. Randomized clinical trials, observational studies, and retrospective cohorts conducted in humans that assessed the effects of semaglutide on body composition, lean mass, and sarcopenia-related functional outcomes were included. A total of 19 studies were analyzed. Semaglutide was consistently associated with significant weight loss, primarily driven by fat mass reduction. An absolute reduction in lean mass was observed; however, it was proportionally smaller relative to total weight loss, resulting in a favorable redistribution of body composition. Muscle function outcomes were heterogeneous, with functional preservation in non-elderly adults and a higher risk of functional decline in older and clinically vulnerable populations. In conclusion, semaglutide promotes favorable changes in body composition; however, its effects on lean mass and muscle function are highly dependent on patient characteristics. Although no direct causal relationship with sarcopenia has been established, monitoring of muscle mass and function is recommended, particularly in older adults, along with integrated strategies such as resistance training and adequate protein intake to mitigate potential musculoskeletal risks.
- 24 February 2026
- Published by Seven Events
- p. 416-427
Open AccessIMPACT OF SEMAGLUTIDE USE ON LEAN MASS AND SARCOPENIA RISK: AN INTEGRATIVE REVIEW OF CLINICAL EVIDENCE
Semaglutide has emerged as an effective pharmacological strategy for the management of obesity and type 2 diabetes mellitus, promoting significant weight loss. However, its effects on lean mass, muscle function, and the risk of sarcopenia remain under debate, particularly in vulnerable populations such as older adults. The aim of this study was to critically analyze the available clinical evidence regarding the impact of semaglutide on lean mass and sarcopenia risk. This narrative review was conducted based on systematic searches in the PubMed/MEDLINE, SciELO, and ScienceDirect databases, including studies published between 2015 and 2025. Randomized clinical trials, observational studies, and retrospective cohorts conducted in humans that assessed the effects of semaglutide on body composition, lean mass, and sarcopenia-related functional outcomes were included. A total of 19 studies were analyzed. Semaglutide was consistently associated with significant weight loss, primarily driven by fat mass reduction. An absolute reduction in lean mass was observed; however, it was proportionally smaller relative to total weight loss, resulting in a favorable redistribution of body composition. Muscle function outcomes were heterogeneous, with functional preservation in non-elderly adults and a higher risk of functional decline in older and clinically vulnerable populations. In conclusion, semaglutide promotes favorable changes in body composition; however, its effects on lean mass and muscle function are highly dependent on patient characteristics. Although no direct causal relationship with sarcopenia has been established, monitoring of muscle mass and function is recommended, particularly in older adults, along with integrated strategies such as resistance training and adequate protein intake to mitigate potential musculoskeletal risks.
- Open Access
- 13 January 2026
- Published by Seven Events
- p. 43-55
ORAL GLP-1 RECEPTOR AGONIST (ORFORGLIPRON) IN THE MANAGEMENT OF OBESITY AND TYPE 2 DIABETES
Orforglipron (LY3502970) is the first small-molecule, non-peptidic oral agonist of the glucagon-like peptide-1 (GLP-1) receptor, developed for the treatment of obesity and type 2 diabetes mellitus (T2DM). This study conducted a narrative literature review, of a descriptive and qualitative nature, aiming to compile and critically analyze scientific evidence published between 2015 and 2025 regarding the pharmacology, clinical efficacy, safety, and therapeutic applicability of this agent. The literature search was performed in PubMed, SciELO, ScienceDirect, and ClinicalTrials.gov, using controlled descriptors from the DeCS and MeSH vocabularies. A total of 19 studies, including randomized clinical trials, systematic reviews, and meta-analyses, were included. Findings demonstrated mean reductions in glycated hemoglobin (HbA1c) of 1.3–1.6% and body weight loss of 10–15%, with a favorable safety profile and mild to moderate gastrointestinal effects. Additionally, improvements were observed in cardiometabolic parameters, such as blood pressure, LDL cholesterol, and high-sensitivity C-reactive protein, suggesting a possible indirect cardioprotective effect. In conclusion, Orforglipron represents a significant innovation in metabolic therapy, combining clinical efficacy, dosing convenience, and potential cardiovascular benefit. However, its clinical consolidation will depend on the completion of ongoing phase 3 multicenter trials, which are expected to confirm its effects on long-term clinical outcomes.
- 13 January 2026
- Published by Seven Events
- p. 43-55
Open AccessORAL GLP-1 RECEPTOR AGONIST (ORFORGLIPRON) IN THE MANAGEMENT OF OBESITY AND TYPE 2 DIABETES
Orforglipron (LY3502970) is the first small-molecule, non-peptidic oral agonist of the glucagon-like peptide-1 (GLP-1) receptor, developed for the treatment of obesity and type 2 diabetes mellitus (T2DM). This study conducted a narrative literature review, of a descriptive and qualitative nature, aiming to compile and critically analyze scientific evidence published between 2015 and 2025 regarding the pharmacology, clinical efficacy, safety, and therapeutic applicability of this agent. The literature search was performed in PubMed, SciELO, ScienceDirect, and ClinicalTrials.gov, using controlled descriptors from the DeCS and MeSH vocabularies. A total of 19 studies, including randomized clinical trials, systematic reviews, and meta-analyses, were included. Findings demonstrated mean reductions in glycated hemoglobin (HbA1c) of 1.3–1.6% and body weight loss of 10–15%, with a favorable safety profile and mild to moderate gastrointestinal effects. Additionally, improvements were observed in cardiometabolic parameters, such as blood pressure, LDL cholesterol, and high-sensitivity C-reactive protein, suggesting a possible indirect cardioprotective effect. In conclusion, Orforglipron represents a significant innovation in metabolic therapy, combining clinical efficacy, dosing convenience, and potential cardiovascular benefit. However, its clinical consolidation will depend on the completion of ongoing phase 3 multicenter trials, which are expected to confirm its effects on long-term clinical outcomes.
- 6 January 2026
- Published by Seven Events
COMPARISON BETWEEN BARIATRIC SURGERY AND TIRZEPATIDE (MOUNJARO®) IN REDUCING CARDIOVASCULAR RISK IN OBESE PATIENTS
Obesity is a chronic multifactorial disease associated with high cardiovascular morbidity and mortality, resulting from complex interactions among metabolic, hormonal, and inflammatory factors. In recent decades, surgical and pharmacological therapeutic strategies have been extensively investigated to reduce cardiometabolic risk in individuals with obesity. This study aimed to compare scientific evidence on the effects of bariatric surgery and tirzepatide (Mounjaro®) in reducing cardiovascular risk in obese patients. This is an integrative and comparative review with a qualitative–quantitative approach, developed from articles published between 2015 and 2025 in the PubMed, SciELO, ScienceDirect, and AHA Journals databases. Twenty studies were analyzed, including clinical trials, meta-analyses, and systematic reviews, of which fifteen demonstrated higher methodological relevance and were used in the comparative synthesis of findings. The results showed that bariatric surgery, particularly the Roux-en-Y gastric bypass and sleeve gastrectomy techniques, promotes a significant reduction in cardiovascular mortality, improvement in glycemic and lipid profiles, and a decrease in systemic inflammatory markers. Tirzepatide, in turn, demonstrated a marked impact on weight loss, insulin sensitivity, and improvement of inflammatory and hemodynamic parameters, with a cardioprotective effect comparable to that observed after metabolic surgery. It is concluded that both approaches constitute effective and complementary strategies for the prevention and management of cardiovascular diseases associated with obesity, representing promising perspectives for contemporary metabolic medicine.
- 6 January 2026
- Published by Seven Events
COMPARISON BETWEEN BARIATRIC SURGERY AND TIRZEPATIDE (MOUNJARO®) IN REDUCING CARDIOVASCULAR RISK IN OBESE PATIENTS
Obesity is a chronic multifactorial disease associated with high cardiovascular morbidity and mortality, resulting from complex interactions among metabolic, hormonal, and inflammatory factors. In recent decades, surgical and pharmacological therapeutic strategies have been extensively investigated to reduce cardiometabolic risk in individuals with obesity. This study aimed to compare scientific evidence on the effects of bariatric surgery and tirzepatide (Mounjaro®) in reducing cardiovascular risk in obese patients. This is an integrative and comparative review with a qualitative–quantitative approach, developed from articles published between 2015 and 2025 in the PubMed, SciELO, ScienceDirect, and AHA Journals databases. Twenty studies were analyzed, including clinical trials, meta-analyses, and systematic reviews, of which fifteen demonstrated higher methodological relevance and were used in the comparative synthesis of findings. The results showed that bariatric surgery, particularly the Roux-en-Y gastric bypass and sleeve gastrectomy techniques, promotes a significant reduction in cardiovascular mortality, improvement in glycemic and lipid profiles, and a decrease in systemic inflammatory markers. Tirzepatide, in turn, demonstrated a marked impact on weight loss, insulin sensitivity, and improvement of inflammatory and hemodynamic parameters, with a cardioprotective effect comparable to that observed after metabolic surgery. It is concluded that both approaches constitute effective and complementary strategies for the prevention and management of cardiovascular diseases associated with obesity, representing promising perspectives for contemporary metabolic medicine.
- Open Access
- 1 January 2026
- Published by Seven Events in LUMEN ET VIRTUS
- Vol. 17 (56) , e11752
AGONISTA ORAL DE GLP-1 (ORFORGLIPRON) NO MANEJO DA OBESIDADE E DO DIABETES TIPO 2
O Orforglipron (LY3502970) é o primeiro agonista oral do receptor do peptídeo semelhante ao glucagon tipo 1 (GLP-1) desenvolvido na forma não peptídica de molécula pequena, destinado ao tratamento da obesidade e do diabetes mellitus tipo 2 (DM2). Este estudo consistiu em uma revisão narrativa da literatura, de caráter descritivo e qualitativo, com o objetivo de reunir e analisar criticamente as evidências científicas publicadas entre 2015 e 2025 sobre a farmacologia, eficácia clínica, segurança e aplicabilidade terapêutica do fármaco. A busca bibliográfica foi realizada nas bases PubMed, SciELO, ScienceDirect e ClinicalTrials.gov, utilizando descritores controlados dos vocabulários DeCS e MeSH. Foram incluídos 19 estudos, entre ensaios clínicos randomizados, revisões sistemáticas e meta-análises, que demonstraram reduções médias de hemoglobina glicada (HbA1c) entre 1,3% e 1,6% e perda ponderal de 10% a 15%, com perfil de segurança favorável e efeitos gastrointestinais leves a moderados. Além disso, observou-se melhora de parâmetros cardiometabólicos, como pressão arterial, colesterol LDL e proteína C-reativa ultrassensível, indicando possível efeito cardioprotetor indireto. Conclui-se que o Orforglipron representa uma inovação relevante na terapêutica metabólica, ao combinar eficácia clínica, conveniência posológica e potencial benefício cardiovascular. No entanto, sua consolidação clínica dependerá da conclusão dos ensaios multicêntricos de fase 3, que deverão confirmar seus efeitos em desfechos clínicos de longo prazo.
- 1 January 2026
- Published by Seven Events in LUMEN ET VIRTUS
- Vol. 17 (56) , e11752
Open AccessAGONISTA ORAL DE GLP-1 (ORFORGLIPRON) NO MANEJO DA OBESIDADE E DO DIABETES TIPO 2
O Orforglipron (LY3502970) é o primeiro agonista oral do receptor do peptídeo semelhante ao glucagon tipo 1 (GLP-1) desenvolvido na forma não peptídica de molécula pequena, destinado ao tratamento da obesidade e do diabetes mellitus tipo 2 (DM2). Este estudo consistiu em uma revisão narrativa da literatura, de caráter descritivo e qualitativo, com o objetivo de reunir e analisar criticamente as evidências científicas publicadas entre 2015 e 2025 sobre a farmacologia, eficácia clínica, segurança e aplicabilidade terapêutica do fármaco. A busca bibliográfica foi realizada nas bases PubMed, SciELO, ScienceDirect e ClinicalTrials.gov, utilizando descritores controlados dos vocabulários DeCS e MeSH. Foram incluídos 19 estudos, entre ensaios clínicos randomizados, revisões sistemáticas e meta-análises, que demonstraram reduções médias de hemoglobina glicada (HbA1c) entre 1,3% e 1,6% e perda ponderal de 10% a 15%, com perfil de segurança favorável e efeitos gastrointestinais leves a moderados. Além disso, observou-se melhora de parâmetros cardiometabólicos, como pressão arterial, colesterol LDL e proteína C-reativa ultrassensível, indicando possível efeito cardioprotetor indireto. Conclui-se que o Orforglipron representa uma inovação relevante na terapêutica metabólica, ao combinar eficácia clínica, conveniência posológica e potencial benefício cardiovascular. No entanto, sua consolidação clínica dependerá da conclusão dos ensaios multicêntricos de fase 3, que deverão confirmar seus efeitos em desfechos clínicos de longo prazo.